// App-Quantinova.ai

918 : Safety, Tolerability and Pharmacokinetics of GSK3389404, an Antisense Oligonucleotide for the Treatment of Chronic Hepatitis B (CHB) Infection: A Randomized, Double‐Blind, Placebo‐Controlled, Dose‐Escalation, First Time in Human Study

Researchers

Presenter

  • Kelong Han

Principal Investigators

  • Jennifer Kim

  • Rob Elston

  • Stuart Oliver

  • Sharon Baptiste-Brown

  • Shuguang Chen

  • Soumi Lahiri

  • David Gardiner

  • Matt Davies

  • Frans van den Berg

  • Melani Paff

  • Dickens Theodore

Medical Centers

  • GSK, King of Prussia, PA

  • Hammersmith Medicines Research, London, United Kingdom

  • QuintilesIMS, London, United Kingdom

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Infectious Diseases (ID)

Disease

  • Hepatitis B

Biomarkers

  • N/A

Drug/Treatment

  • IONIS HBV LRx

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Pharmacokinetics

  • Double Blind/Blinded

  • Controlled

Phase

  • II

Study Id's

  • NCT02647281

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved